Comparison Between Nab-paclitaxel and Solvent-based Taxanes As Neoadjuvant Therapy in Breast Cancer: a Systematic Review and Meta-analysis

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2021 Feb 5

PMID 33541289

Citations 10

Authors

Miao Liu

Siyao Liu

Liu Yang

Shu Wang

Affiliations

Soon will be listed here.

Abstract

Background: To compare the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and solvent-based taxanes (sb-taxanes) as neoadjuvant therapy in the treatment of breast cancer.

Methods: We systematically searched the PubMed, Embase, and Cochrane Central Register databases. Randomized controlled trials (RCTs) and cohort studies, published in English, about the comparison between nab-paclitaxel and sb-taxanes as neoadjuvant therapy in patients with breast cancer were searched up to September 2019.

Results: The primary outcome was the proportion of patients with pathological complete response (pCR, defined as ypT0 ypN0 or ypT0/is ypN0). Other main outcomes included long-term survival and adverse events (AEs). Seven studies (five RCTs and two cohorts) and 2949 patients were included. Neoadjuvant nab-paclitaxel improved pCR compared with sb-taxanes (ypT0 ypN0: OR = 1.52, 95%CI: 1.27-1.83, P < 0.001; ypT0/is ypN0: OR = 1.40, 95%CI: 1.17-1.68, P < 0.001). The benefits of nab-paclitaxel on pCR were persistent in HER2-negative, hormone receptor (HR)-positive breast cancer (OR = 1.53, 95%CI: 1.07-2.19, P = 0.020), triple-negative breast cancer (weekly/every 2 weeks regimen; OR = 2.95, 95%CI: 1.54-5.67, P < 0.001), and tumors with Ki-67 > 20% (OR = 1.63, 95%CI: 1.26-2.12, P < 0.001). Patients treated with nab-paclitaxel had better event-free survival (EFS; HR = 0.69, 95%CI: 0.57-0.85, P < 0.001) than with sb-taxanes. There were no differences in most of grade > 3 AEs between nab-paclitaxel and sb-taxanes (all P > 0.05), besides of any grade hypersensitivity (OR = 0.29, 95%CI: 0.11-0.72, P = 0.008), any grade (OR = 2.10, 95%CI: 1.37-3.23, P = 0.001) and grade > 3 (OR = 4.01, 95%CI: 2.51-6.41, P < 0.001) neuropathy.

Conclusion: Nab-paclitaxel is effective for the treatment of non-metastatic breast cancer in the neoadjuvant setting. Nab-paclitaxel could improve pCR rate and EFS compared with sb-taxanes and with reasonable toxicities.

Citing Articles

Formulation-dependent differences in paclitaxel distribution to anatomical sites relevant to chemotherapy-induced peripheral neuropathy.

Girdenyte M, Hu Y, Ginosyan A, Hammarlund-Udenaes M, Loryan I Front Pharmacol. 2024; 15:1486686.

PMID: 39568585 PMC: 11576287. DOI: 10.3389/fphar.2024.1486686.

Molecular Docking and Pharmacokinetic Profiling of Nab-paclitaxel as Advanced Chemotherapeutic Agent Against HER-2 Positive Breast Cancer Patients.

Mangilit N, Arkoncel A, Baylon K, Eslabra J, De Borja J, Nakama J Asian Pac J Cancer Prev. 2024; 25(10):3447-3456.

PMID: 39471010 PMC: 11711331. DOI: 10.31557/APJCP.2024.25.10.3447.

Paclitaxel Drug-Drug Interactions in the Military Health System.

Luong T, Shou K, Reinhardt B, Kigelman O, Greenfield K Fed Pract. 2024; 41(Suppl 3):S70-S82.

PMID: 39411396 PMC: 11473118. DOI: 10.12788/fp.0499.

Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.

Qin J, Xue L, Hao A, Guo X, Jiang T, Ni Y Nat Med. 2024; 30(9):2549-2557.

PMID: 38956195 PMC: 11405280. DOI: 10.1038/s41591-024-03064-w.

Efficacy of the traditional Chinese medicine, Buyang Huanwu Decoction, at preventing taxane-induced peripheral neuropathy in breast cancer patients: A prospective, randomized, controlled study.

Luo F, Wan D, Liu J, Chen D, Yuan M, Zhang C Medicine (Baltimore). 2024; 103(9):e37338.

PMID: 38428887 PMC: 10906625. DOI: 10.1097/MD.0000000000037338.

References

Huang X, Lin J, Demner-Fushman D . Evaluation of PICO as a knowledge representation for clinical questions. AMIA Annu Symp Proc. 2007; :359-63. PMC: 1839740. View

Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C . Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol. 2016; 17(3):345-356. DOI: 10.1016/S1470-2045(15)00542-2. View

Kuwayama T, Nakamura S, Hayashi N, Takano T, Tsugawa K, Sato T . Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2 Early-stage Breast Cancer. Clin Breast Cancer. 2018; 18(6):474-480. DOI: 10.1016/j.clbc.2018.06.012. View

Yardley D . nab-Paclitaxel mechanisms of action and delivery. J Control Release. 2013; 170(3):365-72. DOI: 10.1016/j.jconrel.2013.05.041. View

Gelderblom H, Verweij J, Nooter K, Sparreboom A . Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001; 37(13):1590-8. DOI: 10.1016/s0959-8049(01)00171-x. View

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View

Harbeck N, Gnant M . Breast cancer. Lancet. 2016; 389(10074):1134-1150. DOI: 10.1016/S0140-6736(16)31891-8. View

Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, Wolmark N . Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014; 384(9938):164-72. DOI: 10.1016/S0140-6736(13)62422-8. View

Kong X, Moran M, Zhang N, Haffty B, Yang Q . Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer. 2011; 47(14):2084-90. DOI: 10.1016/j.ejca.2011.06.014. View

10.

Cardoso F, Costa A, Senkus E, Aapro M, Andre F, Barrios C . 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2017; 28(1):16-33. PMC: 5378224. DOI: 10.1093/annonc/mdw544. View

11.

Azambuja E, Durbecq V, Rosa D, Colozza M, Larsimont D, Piccart-Gebhart M . HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer. Ann Oncol. 2007; 19(2):223-32. DOI: 10.1093/annonc/mdm352. View

12.

Lobo C, Lopes G, Baez O, Castrellon A, Ferrell A, Higgins C . Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2010; 123(2):427-35. DOI: 10.1007/s10549-010-1002-0. View

13.

Deeks J, Dinnes J, DAmico R, Sowden A, Sakarovitch C, Song F . Evaluating non-randomised intervention studies. Health Technol Assess. 2003; 7(27):iii-x, 1-173. DOI: 10.3310/hta7270. View

14.

Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E . Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v8-30. DOI: 10.1093/annonc/mdv298. View

15.

Gener P, Gouveia L, Sabat G, Rafael D, Fort N, Arranja A . Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells. Nanomedicine. 2015; 11(8):1883-92. DOI: 10.1016/j.nano.2015.07.009. View

16.

Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A . Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006; 12(4):1317-24. DOI: 10.1158/1078-0432.CCR-05-1634. View

17.

Huang L, Chen S, Yao L, Liu G, Wu J, Shao Z . Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer. Int J Nanomedicine. 2015; 10:1969-75. PMC: 4362893. DOI: 10.2147/IJN.S77000. View

18.

Gianni L, Kearns C, Giani A, Capri G, Vigano L, Lacatelli A . Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol. 1995; 13(1):180-90. DOI: 10.1200/JCO.1995.13.1.180. View

19.

Battisti N, True V, Chaabouni N, Chopra N, Lee K, Shepherd S . Pathological complete response to neoadjuvant systemic therapy in 789 early and locally advanced breast cancer patients: The Royal Marsden experience. Breast Cancer Res Treat. 2019; 179(1):101-111. DOI: 10.1007/s10549-019-05444-0. View

20.

Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C . NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. J Clin Oncol. 2019; 37(25):2226-2234. DOI: 10.1200/JCO.18.01842. View